Our antibody drug discovery platforms, utilizing Ablexis’ AlivaMab® Mouse, are optimized for the discovery of therapeutic antibodies that move seamlessly into development. Accelerated timelines and reduced developability risks are achieved with naturally selected fully human variable domains, advanced antibody discovery workflows, integration of reliable, predictive screening cascades, and rapid identification of candidates that meet target product profile requirements.
We have extensive experience in bispecific and CAR antibody engineering. We believe the best biologic drugs are selected from panels of antibodies with diverse sequences, broad epitope coverage, a range of affinities, and favorable biophysical properties. By coupling our discovery workflows with engineering pipelines, we ensure that high-quality antibody variable domains are employed. We leverage assay experience gained during discovery to rapidly evaluate engineered antibody activity.
